Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

2.115 -0.005 (-0.24%)
Streaming Delayed Price Updated: 12:39 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
These Apple Insiders Are Selling Shares of AAPL Stock ↗
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL. 
Via InvestorPlace
News headline image
Why Is Nvni Group (NVNI) Stock Down 8% Today? ↗
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger. 
Via InvestorPlace
News headline image
Why Is Gain Therapeutics (GANX) Stock Moving Today? ↗
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
Via InvestorPlace
News headline image
Expert Ratings for Gain Therapeutics ↗
 
Via Benzinga
News headline image
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Gain Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations for Gain Therapeutics's Future ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗
 
Via Benzinga
News headline image
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Via Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
--News Direct-- 
Via News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,... 
Via TheNewswire.com
News headline image
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at the Jefferies Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.